Meiji Yasuda Asset Management Co Ltd. Buys Shares of 4,890 Illumina, Inc. $ILMN

Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,890 shares of the life sciences company’s stock, valued at approximately $860,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Capital World Investors boosted its holdings in Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after acquiring an additional 124,323 shares during the period. BlackRock Inc. purchased a new stake in Illumina in the second quarter worth $3,374,423,000. State Street Corp lifted its position in shares of Illumina by 3.2% during the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after purchasing an additional 190,324 shares during the last quarter. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Up 0.8%

Shares of NASDAQ ILMN opened at $224.99 on Wednesday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $226.84. The stock’s fifty day simple moving average is $190.35 and its two-hundred day simple moving average is $153.78. The stock has a market capitalization of $33.97 billion, a PE ratio of 41.98, a price-to-earnings-growth ratio of 3.14 and a beta of 1.45. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the company posted $1.19 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares of the company’s stock, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ILMN. Citigroup raised their price target on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. TD Cowen upped their target price on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Royal Bank Of Canada raised their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. boosted their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.